Author of

• 20171

  +

  P2.07 - Immunology and Immunotherapy (ID 708)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Immunology and Immunotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23382

    +

    P2.07-007 - Retrospective Analysis of Antitumor Effects and Biomarkers of Nivolumab in NSCLC Patients with EGFR Mutations (ID 7988)

    09:30 - 09:30  |  Author(s): Y. Mishina
    • Abstract

    Background:
    Randomized phase III trials demonstrated that nivolumab was significantly more efficacious than docetaxel in previously treated NSCLC patients; however, subgroup analysis indicated that nivolumab had no superior antitumor effects in patients with EGFR mutations. Recent studies have shown that predictive biomarkers, such as PD-L1 expression on tumor cells and infiltration of CD8[+] T cells into tumor tissues, were associated with response to nivolumab. The present study was conducted to evaluate the antitumor effects and biomarkers of nivolumab in NSCLC patients with EGFR mutations.
    
    Method:
    We retrospectively assessed 8 EGFR-mutated NSCLC patients treated with nivolumab.
    
    Result:
    All patients had adenocarcinoma histology. Six patients had 19 deletion, 1 had L858R and 1 had S768I point mutations. During nivolumab treatment, no patients achieved partial response and stable disease. Seven patients had progressive disease and 1 was not evaluable. The median number of cycles was only 2. The median progression free survival and median overall survival from the beginning of nivolumab was 32 days (95% C.I. 7 to 51) and 370 days (95% C.I. 230 to 480). PD-L1 expression (28-8 pharmDx) was observed in 3/2/1 patients before the start of nivolumab using cutoffs of >1%, >5% and >50% tumor cell staining. Immunohistochemistry revealed that CD4[+] and CD8[+] tumor infiltrating lymphocytes were observed in all patients before nivolumab.
    
    Conclusion:
    The current study indicated that nivolumab was not effective in patients with EGFR mutations regardless of predictive biomarkers of nivolumab.